Get the Stockscreener App
10.72
4.11%
-0.46
After Hours:
10.53
-0.19
-1.77%
Korro Bio Inc stock is traded at $10.72, with a volume of 187.44K.
It is down -4.11% in the last 24 hours and down -14.85% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
See More
Previous Close:
$11.18
Open:
$11.09
24h Volume:
187.44K
Relative Volume:
1.07
Market Cap:
$154.61M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-0.8589
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
-20.06%
1M Performance:
-14.85%
6M Performance:
+52.71%
1Y Performance:
-13.20%
1-Day Range:
$10.46
$11.28
1-Week Range:
$10.46
$13.48
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
10.72 | 161.24M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio CEO Ram Aiyar sells $196,672 in company stock - Investing.com
Korro Bio CEO Ram Aiyar sells $196,672 in company stock By Investing.com - Investing.com UK
Korro Bio director sells $39,897 in common stock By Investing.com - Investing.com Australia
Korro Bio director sells $39,897 in common stock - Investing.com
Korro Bio Inc. (KRRO) Faces Selling Pressure as Shares Retreat 3.21%Bear Pennant - The Legal Advocate
KRRO Q1 2026 Earnings: EPS Beat by 10.05% as Biotech Advances PipelineNext Quarter Guidance - The Legal Advocate
Press Release: Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors - Moomoo
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
Korro Bio, Inc. identifies surge in healthcare burden from ammonia in hepatic encephalopathy - Traders Union
Korro Bio (KRRO) Receives a Buy from H.C. Wainwright - The Globe and Mail
Korro to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Stock Climbs Before Holiday; Bigger Test Still to Come - Bez Kabli
Korro Bio Inc. (KRRO) Surges Nearly 12% as Biotech Momentum BuildsExpert Momentum Signals - Newser
Citigroup initiates coverage of Korro Bio (KRRO) with buy recommendation - MSN
Korro Bio Selects KRRO-111 as RNA Editing Therapy Candidate for Alpha-1 Antitrypsin Deficiency (AATD) with Best-in-Class Preclinical Results 1 - Minichart
Korro Bio, Inc.Common Stock (NQ: KRRO - The Chronicle-Journal
Korro Bio adds AATD treatment candidate to pipeline By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Korro Bio stock price target on financing impact By Investing.com - Investing.com South Africa
Korro Bio nominates new candidate for AATD - BioWorld News
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Korro Bio, Inc. selects KRRO-111 after preclinical success in repairing AAT protein - Traders Union
H.C. Wainwright cuts Korro Bio stock price target on financing impact - Investing.com Nigeria
Korro Bio Advances KRRO-111 for Alpha-1 Deficiency - TipRanks
Korro Bio adds AATD treatment candidate to pipeline - Investing.com
KRRO Initiates Coverage by Citigroup -- Announces Buy Rating - GuruFocus
Citi Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $21 - Moomoo
Lynx1 Capital Management LP's Korro Bio Inc(KRRO) Holding History - GuruFocus
Citigroup Initiates Korro Bio at Buy With $21 Price Target - marketscreener.com
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Should You Sell Korro Bio (KRRO) After -8.12% Drop? 2026-05-15Stock Picks - Newser
Korro Bio, Inc. advances KRRO-121 RNA editing therapy for hyperammonemia toward clinical stage - Traders Union
New Korro Bio hire gets option for 3,000 shares at $11.20 - Stock Titan
TradingKey - TradingKey
Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN
Korro announces oversubscribed $85 million private placement - MSN
Number of shareholders of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Korro Bio (NASDAQ:KRRO) Announces Quarterly Earnings Results - MarketBeat
Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus
JonesTrading Upgrades Korro Bio(KRRO.US) to Buy Rating, Announces Target Price $23 - Moomoo
Jones Trading upgrades Korro Bio stock rating on AATD program potential By Investing.com - Investing.com South Africa
Jones Trading upgrades Korro Bio stock rating on AATD program potential - Investing.com Nigeria
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FORMELA JEAN FRANCOIS | Director |
May 28 '26 |
Sale |
13.95 |
2,860 |
39,897 |
194,655 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):